Nina Lin
Infectious Disease · Boston, MANPI 1528021029
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,350 of the $7,924 with a category attached, or 92.8%. 4 manufacturers reported payments, led by Roche Diagnostics Corporation at 43.8% of the total. Reporting peaked in 2021 at $3,660 and has fallen 98.7% since, to $47 in 2024.
Across 11 payments — averaging $720.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics Corporation$3K
- Viiv Healthcare Company$3K
- Gilead$2K
- Novo Nordisk$47
Across 34 payments — averaging $27,025 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$564K
- Hoffmann-la Roche Limited$308K
- Gilead$33K
- Viiv Healthcare Company$14K
What the payments were for
- Consulting fees$7,35093%
- Travel & lodging$2263%
- Food & beverage$3484%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics Corporation | 5 | $3,468 |
| Viiv Healthcare Company | 3 | $2,819 |
| Gilead | 2 | $1,590 |
| Novo Nordisk | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,924 in reported general payments places this provider in the 85th percentile of 368 infectious disease providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 102 | $389,086 |
| CabenuvaCabotegravir/Rilpivirine | 12 | $75,594 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 21 | $73,941 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 17 | $60,313 |
| TivicayDolutegravir Sodium | 27 | $58,428 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $23,462 |
| PrezistaDarunavir | 12 | $22,848 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,819 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $1,074 |
| Gabapentin | 30 | $274 |
| Omeprazole | 20 | $244 |
| Atorvastatin Calcium | 43 | $220 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 14 | $220 |
| Rosuvastatin Calcium | 19 | $210 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 11 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,590 | $486,489134 claims |
| Viiv Healthcare CompanyCabenuva, Tivicay | $2,819 | $134,02139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 368 infectious disease providers in Massachusetts.
Other infectious disease in Boston
- Yoav GolanBoston$1.1M
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Paul SaxBoston$320K
- Davidson HamerBoston$221K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Eric RosenbergBoston$134K
- Deborah HungBoston$130K
- Laura KogelmanBoston$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.